“Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s241. doi:10.25251/skin.7.supp.241.